Yuheng Pharmaceutical announced that the company signed a “technology transfer contract” with Capital Medical University to obtain an invention patent for “a marker and application of calcium overload mediates neuron death” for 11.15 million yuan. The patent intends to develop a gene therapy targeting TLK2. It is currently in the early stages of development and is expected to enter the clinical needs of retinal ganglion cell neuroprotection in the field of glaucoma. The transfer price is paid in installments according to the milestone schedule. This transaction does not constitute a related transaction or major asset restructuring, and will not have a significant impact on the company's financial situation and operating performance this year. There is a risk that research and development of the project will fall short of expectations.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.